The Cellular Signalling Landscape of Migraine: Insights into Pathophysiology and Intervention

Dr. Kartikey[1], Prof. Dr Dinesh Chandra Shashtri[2]
[1]*PhD scholar, Ved Vibhag, Gurukul Kangri, Deemed to be University, Haridwar*
[2]*Vice Chancellor, Uttarakhand Sanskrit University, Haridwar*

***Abstract*- Migraine is a complex neurological disorder characterised by recurrent headaches[1] and associated symptoms such as photophobia, phonophobia, and nausea. Recent advances in neurobiology have highlighted the pivotal role of cell signalling pathways in the pathogenesis of migraine[2]. This review synthesises current knowledge on the involvement of neuronal, glial, and immune cell signalling in migraine, focusing on molecular mediators, genetic factors, and neuroinflammatory processes. We discuss the implications of these findings for the development of targeted therapies and future research directions.**

***Index Terms*- cell signal, migraine**

I. INTRODUCTION

Migraine affects over one billion people worldwide[3] and is a leading cause of disability. Despite its prevalence, the precise mechanisms underlying migraine remain incompletely understood. Traditional theories have focused on vascular changes and neuronal hyperexcitability, but emerging evidence points to a central role for cell-signalling pathways involving neurons, glia, and immune cells in both the initiation and propagation of migraine attacks. Understanding these pathways is crucial for identifying novel therapeutic targets and improving patient outcomes.

II. PATHOPHYSIOLOGY OF MIGRAINE: AN OVERVIEW

The Trigeminovascular System

The trigeminovascular system (TVS) is central to migraine pathophysiology. Activation and sensitisation of the TVS lead to the release of neuropeptides, vasodilation, and neurogenic inflammation, which contribute to headache pain1. The TVS comprises trigeminal nerve fibres that innervate cerebral blood vessels and relay nociceptive signals to the brainstem and higher cortical centres.

Cortical Spreading Depression

Cortical spreading depression (CSD) is a wave of neuronal and glial depolarisation that propagates across the cortex and is believed to underlie migraine aura. CSD triggers the release of signalling molecules that activate the TVS and promote neuroinflammation.

III. CELLULAR PLAYERS IN MIGRAINE SIGNALLING

Neurons

Neurons are the primary mediators of pain signalling in migraine. They release neuropeptides such as calcitonin gene-related peptide (CGRP), substance P, and pituitary adenylate cyclase-activating polypeptide (PACAP)[4], which modulate vascular tone and nociceptive transmission. Genetic studies have identified mutations in ion channels and neurotransmitter receptors that increase neuronal excitability and susceptibility to migraine.

Glial Cells

Glial cells, including astrocytes, microglia, oligodendrocytes, Schwann cells, and satellite glial cells, play active roles in migraine pathogenesis. They modulate synaptic transmission, maintain homeostasis, and participate in neuroinflammatory responses. Astrocytes regulate extracellular glutamate and potassium levels, while microglia respond to injury and infection by releasing pro-inflammatory cytokines[5].

Immune Cells

Immune cells, particularly mast cells and B lymphocytes, contribute to migraine by releasing inflammatory mediators and modulating the integrity of the blood-brain barrier. Mast cell degranulation in the meninges leads to the sensitisation of trigeminal afferents, while specific B cell phenotypes may exert protective or risk-modifying effects.

IV. MOLECULAR SIGNALLING PATHWAYS IN MIGRAINE

Calcitonin Gene-Related Peptide (CGRP) Pathway

CGRP is a 37-amino acid neuropeptide released from trigeminal nerve endings during migraine attacks. It acts on a receptor complex composed of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), leading to vasodilation and pain transmission. Elevated CGRP levels are observed during migraine attacks, and CGRP antagonists have shown efficacy in migraine prevention.

Serotonin and Tryptophan-Kynurenine Pathways

Altered serotonin (5-HT) signalling is implicated in migraine susceptibility. The tryptophan-kynurenine (Trp-KYN) pathway influences pain processing, stress response, and neuroinflammation. Migraine patients exhibit altered Trp-KYN metabolism, suggesting a role for these pathways in disease pathogenesis.

Glutamate and Ion Channel Signalling

Glutamate is the principal excitatory neurotransmitter in the central nervous system[6]. Dysregulation of glutamatergic signalling and mutations in ion channels (e.g., CACNA1A, SCN1A) are associated with familial hemiplegic migraine and increased neuronal excitability.

Toll-Like Receptor (TLR) and Inflammasome Pathways

Toll-like receptors (TLRs), particularly TLR4, are expressed on mast cells and microglia. Activation of TLR4 leads to the release of pro-inflammatory cytokine[7] via the MyD88 signalling pathway, contributing to central sensitisation and migraine-like behavior. Inflammasomes, such as NLRP3, are multiprotein complexes that amplify neuroinflammatory responses and may serve as therapeutic targets.

Cytokine and Chemokine Signalling

Pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6) and chemokines mediate cell-cell communication during migraine attacks. These molecules promote the recruitment and activation of immune cells[8], enhance nociceptor sensitivity, and sustain neuroinflammation.

Genetic and Epigenetic Regulation of Cell Signalling in Migraine

Genome-wide association studies (GWAS) have identified numerous genes associated with migraine susceptibility[9], many of which are involved in cell signalling pathways. Single-cell RNA sequencing has localised migraine-associated gene expression to specific neuronal, glial, and neurovascular cell types. Epigenetic modifications, such as DNA methylation and non-coding RNAs, further regulate gene expression and cellular responses in migraine.

Neuroinflammation and Cell Signalling

Neuroinflammation is a hallmark of migraine pathophysiology. Activation of glial cells and immune cells leads to the release of inflammatory mediators that sensitise nociceptors and perpetuate pain[10]. Imaging studies using PET-MRI have demonstrated increased glial activation during migraine attacks. The interplay between neuroinflammatory signalling and neuronal excitability is central to migraine chronification.

Cell-Type Specificity and Heterogeneity

Recent advances in single-cell transcriptomics have revealed the heterogeneity of cell types involved in migraine. Distinct populations of neurons, glia, and immune cells express unique sets of genes and signalling molecules that contribute to disease pathogenesis. This cellular diversity underlies the variability in clinical presentation and treatment response among migraine patients.

V. THERAPEUTIC IMPLICATIONS

Targeting CGRP and Its Receptor

CGRP antagonists and monoclonal antibodies targeting the CGRP pathway have demonstrated effectiveness in preventing migraines, marking a notable advancement in migraine therapy.

Modulation of Neuroinflammatory Pathways

Drugs targeting TLRs, inflammasomes, and pro-inflammatory cytokines are under investigation for their potential to reduce neuroinflammation and migraine frequency.

Personalised Medicine

Understanding the genetic and cellular basis of migraine paves the way for personalised treatment strategies. Biomarkers discovered through techniques such as single-cell sequencing and imaging can help doctors select the most suitable treatments and predict a patient's response to them.

VI. CONCLUSION

Cell signalling pathways involving neurons, glia, and immune cells are central to the pathogenesis of migraine. Advances in molecular biology, genetics, and imaging have deepened our understanding of these processes and identified new therapeutic targets. Continued research into the cellular and molecular mechanisms of migraine will facilitate the

development of more effective and personalised treatments[11].

REFERENCES

[1]. Hammad, M. S., Altarazi, R. E. N., Al Banna, R. N., Al Borno, D. F., & Abu-Naser, S. S. (2023). A Proposed Expert System for Diagnosis of Migraine. https://core.ac.uk/download/573470702.pdf

[2]. Ghasemnejad-Berenji, M. (2021). MTOR inhibition: A double-edged sword in patients with COVID-19? Human Cell. https://doi.org/10.1007/s13577-021-00495-2

[3]. EU panel backs Pfizer & Biohaven's migraine drug Vydura | HealthCare Middle East & Africa Magazine. https://www.healthcaremea.com/eu-panel-backs-pfizer-biohavens-migraine-drug-vydura/

[4]. Immunohistochemical identification of sensory neuropeptides Calcitonin Gene-Related Peptide (CGRP), Substance P and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Efferent Vestibular Nucleus neurons. - International Association for the Study of Pain (IASP). https://www.iasp-pain.org/publications/pain-research-forum/papers-of-the-week/paper/immunohistochemical-identification-of-sensory-neuropeptides-calcitonin-gene-related-peptide-cgrp-substance-p-and-pituitary-adenylate-cyclase-activating-polypeptide-pacap-in-efferent-vestibular-nu/

[5]. Tawbeh, A., Raas, Q., Tahri-Joutey, M., Keime, C., Kaiser, R., Trompier, D., Nasser, B., Bellanger, E., Dessard, M., Hamon, Y., Benani, A., Di Cara, F., Cunha Alves, T., Berger, J., Weinhofer, I., Mandard, S., Cherkaoui-Malki, M., Andreoletti, P., Gondcaille, C., . . . Savary, S. (2023). Immune response of BV-2 microglial cells is impacted by peroxisomal beta-oxidation. Frontiers in Molecular Neuroscience, (),.

[6]. Shen, J. (2014). Glutamate. Elsevier EBooks. https://doi.org/10.1016/b978-0-12-401688-0.00009-4

[7]. Varmazyar, R., Naderi, N., Javid, H., Ghasemi, R., & Pourbadie, H. G. (2025). Neuroprotective Effects of Early TLR4 Blockade with Compound C34 in Temporal Lobe Epilepsy: Alleviation of Neuroinflammation and Apoptosis. Deleted Journal. https://doi.org/10.5812/ijpr-159165

[8]. Jiang, S., Wang, S., Sun, Y., & Zhang, Q. (2014). Medicinal properties of Hericium erinaceus and its potential to formulate novel mushroom-based pharmaceuticals. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-014-5955-5

[9]. Novelli, G., Novelli, G., Cassadonte, C., Sbraccia, P., & Biancolella, M. (2023). Genetics: A Starting Point for the Prevention and the Treatment of Obesity. Nutrients, 15(12), 2782.

[10]. Cohen, J. R., Mathew, A. S., Dourvetakis, K. D., Sanchez-Guerrero, E., Pangeni, R. P., Gurusamy, N., Aenlle, K. K., Ravindran, G., Twahir, A., Isler, D., Sosa-Garcia, S. R., Llizo, A., Bested, A. C., Theoharides, T. C., Klimas, N. G., & Kempuraj, D. (2024). Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders. Cells. https://doi.org/10.3390/cells13060511

[11]. Sing, M. (2018). Delirium postcardiac surgery: Intellectual insufficiency and insufficiently understood. The Journal of Thoracic and Cardiovascular. Surgery. https://doi.org/10.1016/j.jtcvs.2017.09.037